News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Brazil recalled its ambassador to Argentina after Argentine President Javier Milei publicly attacked President Lula and Brazil's judiciary, raising regional diplomatic tensions.
  • Citi expects the Federal Reserve to keep interest rates unchanged at its July meeting, a result investors will view as dovish.
  • Kevin Warsh urged the Fed to focus on underlying inflation measures instead of headline PCE, signaling debate over policy benchmarks.
  • ETF assets in Brazil rose to about 116 billion reais, nearly tripling in two years as investors favored tax-efficient fixed-income products.
  • Major asset managers expanded ETF operations in Brazil to meet demand, increasing supply of fee-efficient fixed-income vehicles.

Latest Articles

Marvell Stock Jumps as Analysts Lift Targets Ahead of Quarterly Results

Marvell Stock Jumps as Analysts Lift Targets Ahead of Quarterly Results

Marvell Technology Inc. shares rose sharply Tuesday morning after a pair of analysts raised price targets and reiterated positive ratings ahead of the company’s quarterly earnings report due Wednesday. Susquehanna Financial set a Street-high target, while Stifel also lifted its outlook, citing momentum in Data Center revenue and strength across Mar…

Goldman Sachs Lowers Taylor Wimpey to Sell, Cuts 12-Month Target to 75p

Goldman Sachs Lowers Taylor Wimpey to Sell, Cuts 12-Month Target to 75p

Goldman Sachs has downgraded Taylor Wimpey Plc to a "sell" recommendation from "neutral" and reduced its 12-month price target to 75 pence from 95 pence. The bank warns that escalating construction costs and weakening pricing in Southern England and London are eroding earnings at a rate materially worse than comparable housebuilders, prompting cuts…

J-Star Holding Subsidiary Receives Central Bank of Taiwan Authorization to Initiate $60 Million Sovereign-Backed Financing Framework through Designated Banks for U.S. Solid-State Battery Expansion ($122.5 Million Project)

J-Star Holding Subsidiary Receives Central Bank of Taiwan Authorization to Initiate $60 Million Sovereign-Backed Financing Framework through Designated Banks for U.S. Solid-State Battery Expansion ($122.5 Million Project)

J-Star Holding’s subsidiary YMA Corporation has obtained authorization from the Central Bank of Taiwan to access a $60 million sovereign-backed financing framework supporting the company’s $122.5 million investment in a 100MWh solid-state battery manufacturing facility in Baytown, Texas. The project aims to bolster U.S. advanced manufacturing capab…

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

Plus Therapeutics announced new health economics data showing their CNSide cerebrospinal fluid assay enables earlier diagnosis and therapeutic management of leptomeningeal metastases (LM), potentially reducing healthcare costs by approximately 33-47%. This was presented at the ISPOR 2026 Annual Meeting and highlights CNSide's impact in lowering inp…

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics announced that the independent Data Safety Monitoring Board (DSMB) has given its sixth consecutive positive recommendation to continue the pivotal Phase 3 Bria-ABC study evaluating Bria-IMT combined with an immune checkpoint inhibitor in metastatic breast cancer patients. The DSMB found no safety concerns. The study is conduct…

Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

Dyne Therapeutics has submitted a Biologics License Application to the U.S. FDA for accelerated approval of z-rostudirsen (DYNE-251), a treatment targeting Duchenne Muscular Dystrophy patients amenable to exon 51 skipping. The submission is based on significant results from the DELIVER trial showing increased dystrophin production and functional im…

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics announced multiple presentations at the 2026 CMSC annual meeting highlighting clinical and real-world data supporting BRIUMVI® (ublituximab-xiiy) as an effective treatment for relapsing forms of multiple sclerosis (RMS). New Phase 4 ENABLE study results demonstrate significant improvements in patient-reported outcomes and sustained …

Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design

Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design

Streamex Corp. (NASDAQ: STEX), a technology company specializing in tokenization of real-world assets, announced the appointment of Kori Handy as Vice President of Product and Design. With 18 years of fintech and SaaS experience, Handy will lead the transformation of Streamex’s GLDY platform and future products to improve user experience and accele…

Applied Aerospace & Defense Files for NYSE IPO to Raise Up to $682.5 Million

Applied Aerospace & Defense Files for NYSE IPO to Raise Up to $682.5 Million

Applied Aerospace & Defense, based in Huntsville, Alabama, filed to sell 32,500,000 shares in an initial public offering on the New York Stock Exchange at a proposed price range of $18 to $21 per share, potentially raising as much as $682.5 million. The company, formed last year through a combination of legacy manufacturers, supplies space and defe…

Micron Shares Jump After UBS Triples Price Target, Citing Multi-Year Contracts and Durable AI Memory Demand

Micron Shares Jump After UBS Triples Price Target, Citing Multi-Year Contracts and Durable AI Memory Demand

Micron Technology stock jumped sharply in premarket trading after UBS raised its price target to $1,625 from $535 and materially lifted EPS estimates for 2027-2029. The bank pointed to multi-year supply agreements with fixed volume commitments and partially fixed pricing, and noted significant DDR volumes are locked in at pricing slightly below cur…

Quantinuum Files for U.S. IPO, Seeks Valuation up to $12.7 Billion

Quantinuum Files for U.S. IPO, Seeks Valuation up to $12.7 Billion

Quantinuum, the quantum computing company spun out of Honeywell and merged with Cambridge Quantum, has filed for a U.S. initial public offering. The Broomfield, Colorado-based firm intends to offer roughly 21,052,632 shares at a price range of $45 to $50 per share, aiming to raise up to $1.05 billion and to reach a market valuation of as much as $1…

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Pharma announced positive independent, blinded biomechanical gait analyses from its Phase 1b/2a CONNECT SCI study demonstrating statistically significant genuine neural recovery with NVG-291 in chronic tetraplegia patients. 100% of treated subjects were responders versus 10% placebo, supporting NVG-291 as a potentially best-in-class restora…

Modine Secures $4 Billion Data-Center Cooling Commitment; Shares Jump 14%

Modine Secures $4 Billion Data-Center Cooling Commitment; Shares Jump 14%

Modine (NYSE:MOD) announced a Long-Term Capacity Agreement to supply more than $4 billion of Airedale data-center cooling products to a strategic customer for deliveries spanning calendar years 2027 through 2029. The company received a $165 million upfront cash payment to support capacity investments and other expenditures needed to meet the commit…

Wacker Chemie Shares Slip After UBS Lowers Rating, Citing Limited Upside

Wacker Chemie Shares Slip After UBS Lowers Rating, Citing Limited Upside

Shares of Wacker Chemie AG fell just over 3% after UBS downgraded the German specialty chemicals group from "buy" to "neutral," arguing that a roughly 40% year-to-date rally has narrowed the stock's potential upside. While UBS lifted its 12-month price target to €104 from €84, the firm highlighted several unresolved catalysts and trimmed earnings a…

Space Stocks Rise as SpaceX IPO Filing Sparks Broad Sector Rally

Space Stocks Rise as SpaceX IPO Filing Sparks Broad Sector Rally

Shares of companies tied to rockets, satellites and related space technologies advanced Tuesday as the market reacted to SpaceX's public filing to begin an initial public offering process. A number of small- and mid-cap space companies posted notable gains in early activity, while the sector overall extended recent momentum tied to the IPO news.

AutoZone EPS Tops Estimates but Revenue Miss Trims Stock Reaction

AutoZone EPS Tops Estimates but Revenue Miss Trims Stock Reaction

AutoZone reported third-quarter adjusted earnings per share that exceeded analyst forecasts, yet a small revenue shortfall prompted a near 4% premarket decline in the stock. The company posted higher net income and continued global store expansion, while gross margin was pressured by a non-cash LIFO effect even as operating expense efficiency impro…